Jennifer R. Brown

机构：Harvard University, Dana-Farber Cancer Institute · ORCID：0000-0003-2040-4961

发表论文 1155 篇 · 总被引 45789 次 · h-index 91

代表论文

• Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO) (2025 · Blood · 被引 8)
• Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study (2025 · Blood · 被引 5)
• Ibrutinib: 10 years and counting (2026 · Blood · 被引 1)
• Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) (2025 · Blood · 被引 1)
• Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3-year results from SEQUOIA arm D (2025 · Blood · 被引 1)
• Association between patient-reported symptoms and clinical outcomes in R/R CLL (2026 · Blood Advances)